Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Repurposing the Repurposing Business Model

This article was originally published in Start Up

Executive Summary

Two recent examples of the difficulties of drug repurposing: Bionaut's ability to find new indications was not sufficient to get a foot in pharma's door without novelty to create barriers to entry to deter fast followers. Sention couldn't generate data fast enough on its L-amphetamine in improving cognitive impairment to counter amphetamine's bad image. (Its second program, even armed with pharma-vetted, baggage-less NCEs in-licensed from Merck, emerged too late to save the company.)

You may also be interested in...



OsteoCorp Inc.

The class of drugs called beta-blockers--long used for heart disease and migraines--also prompts an increase in bone mass. OsteoCorp will repurpose beta blockers to build bone in the treatment of conditions like bone cancer and osteoporosis.

AGI Therapeutics Ltd.

Gastrointestinal specialty pharma AGI Therapeutics has assembled a pipeline of six products, four of which are in Phase II trials. It is concentrating most of its efforts in functional GI disorders--IBS, functional dyspepsia and diarrhea, but its portfolio also includes a controlled-release proton pump inhibitor for a niche of the GERD market. In addition, it has an early-stage program in inflammatory bowel disease.

AGI Therapeutics Ltd.

Gastrointestinal specialty pharma AGI Therapeutics has assembled a pipeline of six products, four of which are in Phase II trials. It is concentrating most of its efforts in functional GI disorders--IBS, functional dyspepsia and diarrhea, but its portfolio also includes a controlled-release proton pump inhibitor for a niche of the GERD market. In addition, it has an early-stage program in inflammatory bowel disease.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091115

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel